Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Bita Fakhri (ucsf)

Description

Summary

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

Official Title

A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

Details

This study will be conducted in 2 parts. Part 1 will evaluate LOXO-338 as monotherapy. If safety and initial evidence of efficacy of LOXO-338 monotherapy are confirmed, part 2 will evaluate the combination of LOXO-338 with the highly selective, noncovalent Bruton's tyrosine kinase (BTK) inhibitor, pirtobrutinib (LOXO-305).

Keywords

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell, BTKi, Hematologic disease, Small lymphocytic lymphoma, BCL-2 inhibitor, CLL, SLL, NHL, Lymphoma, Non-Hodgkin Lymphoma, Lymphoid Leukemia, Mantle-Cell Lymphoma, Pirtobrutinib, LOXO-338, LOXO-338 (Monotherapy)

Eligibility

Locations

  • University of California San Francisco, Medical Center at Paranassus
    San Francisco California 94117 United States
  • City of Hope National Medical Center
    Duarte California 91010-0269 United States

Lead Scientist at University of California Health

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
Study of Oral LOXO-338 in Patients with Advanced Blood Cancers
ID
NCT05024045
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 316 study participants
Last Updated